Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis

1 R. L. Siegel, K. D. Miller, H. E. Fuchs and A. Jemal, Cancer statistics, 2022, CA 72(1) (2022) 7–33; https://doi.org/10.3322/caac.21708 Search in Google Scholar

2 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660 Search in Google Scholar

3 EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, J. Hepatol. 69(1) (2018) 182–236; https://doi.org/10.1016/j.jhep.2018.03.019 Search in Google Scholar

4 J. K. Heimbach, L. M. Kulik, R. S. Finn, C. B. Sirlin, M. M. Abecassis, L. R. Roberts, A. X. Zhu, M. H. Murad and J. A. Marrero, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology 67(1) (2018) 358–380; https://doi.org/10.1002/hep.29086 Search in Google Scholar

5 Y. Chang, S. J. Yu, H. C. Kim, Y. B. Lee, E. J. Cho, J. H. Lee, Y. J. Kim, J. W. Chung and J. H. Yoon, Reappraisal of portal vein tumor thrombosis as a prognostic factor for patients with hepatocellular carcinoma, Gut Liver 18(1)(2024) 156–164; https://doi.org/10.5009/gnl230057 Search in Google Scholar

6 A. Forner, M. Reig and J. Bruix, Hepatocellular carcinoma, Lancet 391(10127) (2018) 1301–1314; https://doi.org/10.1016/s0140-6736(18)30010-2 Search in Google Scholar

7 D. Takizawa, S. Kakizaki, N. Sohara, K. Sato, H. Takagi, H. Arai, K. Katakai, A. Kojima, Y. Matsuzaki and M. Mori, Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis, Dig. Dis. Sci. 52(11) (2007) 3290–3295; https://doi.org/10.1007/s10620-007-9808-2 Search in Google Scholar

8 L. C. Chen, W. Y. Chiou, H. Y. Lin, M. S. Lee, Y. C. Lo, L. W. Huang, C. M. Chang, T. H. Hung, C. W. Lin, K. C. Tseng, D. W. Liu, F. C. Hsu and S. K. Hung, Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial, BMC Cancer 19(1) (2019) Article ID 275 (11 pages); https://doi.org/10.1186/s12885-019-5461-3 Search in Google Scholar

9 M. Reig, A. Forner, J. Rimola, J. Ferrer-Fàbrega, M. Burrel, Á. Garcia-Criado, R. K. Kelley, P. R. Galle, V. Mazzaferro, R. Salem, B. Sangro, A. G. Singal, A. Vogel, J. Fuster, C. Ayuso and J. Bruix, BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update, J. Hepatol. 76(3) (2022) 681–693; https://doi.org/10.1016/j.jhep.2021.11.018 Search in Google Scholar

10 H. Suzuki, M. Mori, C. Kawaguchi, M. Adachi, S. Miura and H. Ishii, Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma, Int. J. Oncol. 14(6) (1999) 1087–1090; https://doi.org/10.3892/ijo.14.6.1087 Search in Google Scholar

11 M. Kudo, K. Ueshima, M. Ikeda, T. Torimura, N. Tanabe, H. Aikata, N. Izumi, T. Yamasaki, S. Nojiri, K. Hino, H. Tsumura, T. Kuzuya, N. Isoda, K. Yasui, H. Aino, A. Ido, N. Kawabe, K. Nakao, Y. Wada, O. Yokosuka, K. Yoshimura, T. Okusaka, J. Furuse, N. Kokudo, K. Okita, P. J. Johnson and Y. Arai, Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial, Gut 69(8) (2020) 1492–1501; https://doi.org/10.1136/gutjnl-2019-318934 Search in Google Scholar

12 Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition), Zhonghua Gan Zang Bing Za Zhi 28(2) (2020) 112–128; https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.004 Search in Google Scholar

13 S. Cheng, M. Chen, J. Cai, J. Sun, R. Guo, X. Bi, W. Y. Lau and M. Wu, Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 ed.), Liver Cancer 9(1) (2020) 28–40; https://doi.org/10.1159/000503685 Search in Google Scholar

14 R. Salem, D. Li, N. Sommer, S. Hernandez, W. Verret, B. Ding and R. Lencioni, Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial, Cancer Med. 10(16) (2021) 5437–5447; https://doi.org/10.1002/cam4.4090 Search in Google Scholar

15 2018 Korean Liver Cancer Association – National Cancer Center Korea, Practice guidelines for the management of hepatocellular carcinoma, Korean J. Radiol. 20(7) (2019) 1042–1113; https://doi.org/10.3348/kjr.2019.0140 Search in Google Scholar

16 J. Yuan, X. Yin, B. Tang, H. Ma, L. Zhang, L. Li, R. Chen, X. Xie and Z. Ren, Transarterial Chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: A propensity score matching study, Biomed. Res. Int. 2019 (2019) Article ID 2141859 (6 pages); https://doi.org/10.1155/2019/2141859 Search in Google Scholar

17 Q. Chen and G. Zhang, Clinical efficacy and safety of TACE combined with sorafenib in the treatment of hepatocellular carcinoma with portal vein thrombus, Chin. Hepatology 24(5) (2019) 573–576; https://doi.org/10.3969/j.issn.1008-1704.2019.05.032 Search in Google Scholar

18 J. Wang, W. Chen, X. Liu and Y. Wu, Transcatheter arterial chemoembolization combined with sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombus, Translat. Med. J. 6(03) (2017) 160–163. Search in Google Scholar

19 Y. Zhang, Z. Gao, Y. Qian, M. Zhang, G. Tan and Z. Liu, Clinical effect analysis of sorafenib combined with TACE in the treatment of liver cancer with portal vein cancer thrombus, Chin. J. Modern Drug Appl. 11(2017) 103–104; https://doi.org/10.14164/j.cnki.cn11-5581/r.2017.19.055 Search in Google Scholar

20 A. Li, Evaluation of the clinical utility of TACE combined with sorafenib in the treatment of primary hepatocellular carcinoma with portal vein tumor thrombus, Master Thesis, 2017. Search in Google Scholar

21 H.-H. Ye, J.-Z. Ye, Z.-B. Xie, Y.-C. Peng, J. Chen, L. Ma, T. Bai, J.-Z. Chen, Z. Lu, H.-G. Qin, B.-D. Xiang and L.-Q. Li, Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein, World J. Gastroenter. 22(13) (2016) 3632–3643. Search in Google Scholar

22 W. Li, Z. Dai, H. Wan, L. Yao, J. Zhu, C. Li, X. Wang, J. Pan and L. Chen, Endovascular implantation of iodine·125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus, Nat. Med. J. China 96(2016) 1838–1842. Search in Google Scholar

23 K. Wang, W. X. Guo, M. S. Chen, Y. L. Mao, B. C. Sun, J. Shi, Y. J. Zhang, Y. Meng, Y. F. Yang, W. M. Cong, M. C. Wu, W. Y. Lau and S. Q. Cheng, Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: A large-scale, multicenter, propensity mathching score analysis, Medicine (Baltimore) 95(11) (2016) Article ID e3015 (10 pages); https://doi.org/10.1097/MD.0000000000003015 Search in Google Scholar

24 J. Hao, Hepatic arterial chemoembolization in combination with sorafenib for primary liver cancer with portal vein tumor thrombus, Master Thesis, 2015. Search in Google Scholar

25 K. Zhu, J. Chen, L. Lai, X. Meng, B. Zhou, W. Huang, M. Cai and H. Shan, Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib – a retrospective controlled study, Radiology 272(1) (2014) 284–293; https://doi.org/10.1148/radiol.14131946 Search in Google Scholar

26 L. Luo and Z. Luo, Efficacy and safety analysis of sorafenib combined with TACE in the treatment of hepatocellular carcinoma with portal vein thrombus, J. Chin. Physician 16(12) (2014) 1699–1701; https://doi.org/10.3760/cma.j.issn.1008-1372.2014.12.037 Search in Google Scholar

27 J. Chen, W. Xi, B. Wu, H. Yu and S. Chen, Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis, Chin. Med. J. 94(33) (2014) 2566–2569; https://doi.org/10.3760/cma.j.issn.0376-2491.2014.33.003 Search in Google Scholar

28 A. R. Jadad, R. A. Moore, D. Carroll, C. Jenkinson, D. J. Reynolds, D. J. Gavaghan and H. J. McQuay, Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1) (1996) 1–12; https://doi.org/10.1016/0197-2456(95)00134-4 Search in Google Scholar

29 J. Shi, E. C. Lai, N. Li, W. X. Guo, J. Xue, W. Y. Lau, M. C. Wu and S. Q. Cheng, A new classification for hepatocellular carcinoma with portal vein tumor thrombus, J. Hepatobiliary Pancreat. Sci. 18(1) (2011) 74–80; https://doi.org/10.1007/s00534-010-0314-0 Search in Google Scholar

30 J. Luo, R. P. Guo, E. C. Lai, Y. J. Zhang, W. Y. Lau, M. S. Chen and M. Shi, Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study, Ann. Surg. Oncol. 18(2) (2011) 413–420; https://doi.org/10.1245/s10434-010-1321-8 Search in Google Scholar

31 C. Shuqun, W. Mengchao, C. Han, S. Feng, Y. Jiahe, D. Guanghui, C. Wenming, W. Peijun and Z. Yuxiang, Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein, Hepatogastroenterology 54(74) (2007) 499–502. Search in Google Scholar

32 M. Abdelrahim, D. Victor, A. Esmail, S. Kodali, E. A. Graviss, D. T. Nguyen, L. W. Moore, A. Saharia, R. McMillan, J. N. Fong, A. Uosef, M. Elshawwaf, K. Heyne and R. M. Ghobrial, Transarterial chemoembolization (TACE) plus sorafenib compared to TACE alone in transplant recipients with hepatocellular carcinoma: An institution experience, Cancers (Basel) 2022(14) (2022) Article ID 650 (13 pages); https://doi.org/10.3390/cancers14030650 Search in Google Scholar

33 S. W. Jeong, J. Y. Jang, K. Y. Shim, S. H. Lee, S. G. Kim, S. W. Cha, Y. S. Kim, Y. D. Cho, H. S. Kim, B. S. Kim, K. H. Kim and J. H. Kim, Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis, Gut Liver. 7(6) (2013) 696–703; https://doi.org/10.5009/gnl.2013.7.6.696 Search in Google Scholar

34 Z. B. Tan and J. Zhang, Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus, Eur. Rev. Med. Pharmacol. Sci. 27(17) (2023) 8119–8134; https://doi.org/10.26355/eurrev_202309_33572 Search in Google Scholar

35 Z. Peng, W. Fan, B. Zhu, G. Wang, J. Sun, C. Xiao, F. Huang, R. Tang, Y. Cheng, Z. Huang, Y. Liang, H. Fan, L. Qiao, F. Li, W. Zhuang, B. Peng, J. Wang, J. Li and M. Kuang, Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A Phase III, randomized clinical trial (LAUNCH), J. Clin. Oncol. 41(1) (2023) 117–127; https://doi.org/10.1200/jco.22.00392 Search in Google Scholar

36 J. Lu, J. H. Guo, J. S. Ji, Y. L. Li, W. F. Lv, H. D. Zhu, J. H. Sun, W. X. Ren, F. J. Zhang, W. D. Wang, H. B. Shao, G. S. Cao, H. L. Li, K. Gao, P. Yang, G. W. Yin, G. Y. Zhu, F. Z. Wu, W. J. Wang, D. Lu, S. Q. Chen, J. Min, Y. Zhao, R. Li, L. G. Lu, W. Y. Lau and G. J. Teng, Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial, Int. J. Surg. 109(5) (2023) 1188–1198; https://doi.org/10.1097/js9.0000000000000295 Search in Google Scholar

37 X. Zou, Q. Xu, R. You and G. Yin, Evaluating the benefits of TACE combined with lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus, Adv. Ther. 40(4) (2023) 1686–1704; https://doi.org/10.1007/s12325-023-02449-6 Search in Google Scholar

38 M. Kudo, R. S. Finn, S. Qin, K. H. Han, K. Ikeda, F. Piscaglia, A. Baron, J. W. Park, G. Han, J. Jassem, J. F. Blanc, A. Vogel, D. Komov, T. R. J. Evans, C. Lopez, C. Dutcus, M. Guo, K. Saito, S. Kraljevic, T. Tamai, M. Ren and A. L. Cheng, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet 391(10126) (2018) 1163–1173; https://doi.org/10.1016/s0140-6736(18)30207-1 Search in Google Scholar

39 A. Guerrero, L. D. Campo, F. Piscaglia, B. Scheiner, G. Han, F. Violi, C. N. Ferreira, L. Téllez, T. Reiberger, S. Basili, J. Zamora and A. Albillos, Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis, J. Hepatol. 79(1) (2023) 69–78; https://doi.org/10.1016/j.jhep.2023.02.023 Search in Google Scholar

40 M. Kicinski, D. A. Springate and E. Kontopantelis, Publication bias in meta-analyses from the Cochrane Database of Systematic Reviews, Stat. Med. 34(20) (2015) 2781–2793; https://doi.org/10.1002/sim.6525 Search in Google Scholar